key: cord-0283975-iodyxo2b
authors: Shapiro, L. C.; Thakkar, A.; Gali, R.; Gonzalez-Lugo, J. D.; Bazarbachi, A.-H.; Rahman, S.; Pradhan, K.; Fehn, K.; Abreu, M.; Kornblum, N.; Gritsman, K.; Goldfinger, M.; Shastri, A.; Mantzaris, I.; Braunschweig, I.; Halmos, B.; Verma, A.; McCort, M.; Bachier-Rodriguez, L.; Sica, R. A.
title: High Seroconversion Rates Amongst Black and Hispanics With Hematologic Malignancies after SARS-CoV-2 Vaccination
date: 2021-09-16
journal: nan
DOI: 10.1101/2021.09.13.21263365
sha: 70c40247da71bc1bef4b2f4b5bdb8a580ba87121
doc_id: 283975
cord_uid: iodyxo2b

It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients with hematologic malignancies, however, very little data on ethnicity specific responses in this particular patient population currently exists. We established a program of rapid vaccination and evaluation of antibody-mediated response to all EUA COVID-19 vaccines in an inner city minority population to determine the factors that contribute to the poor seroconversion to COVID-19 vaccination in this population. We conducted a cross-sectional cohort study of 126 patients with hematologic malignancies in the outpatient practices of our institution who completed their vaccination series with one of the three FDA EUA COVID-19 vaccines, Moderna, Pfizer, or Johnson & Johnson (J&J). We qualitatively measured Spike IgG production in all patients using the AdviseDx SARS-CoV-2 IgG II assay and quantitatively in 106 patients who completed their vaccination series with at least 14 days after the 2nd dose of the Moderna or Pfizer vaccines or 28d after the single J&J vaccine. Patient characteristics were analyzed using standard descriptive statistics and associations between patient characteristics, cancer subtypes, treatments, and vaccine response were assessed using Fisher Exact test or Kruskal-Wallis Rank Sum test. The majority of patients (74%) were minorities. Seventy patients (60%) received Pfizer, 36 patients (31%) Moderna, and 10 patients (9%) J&J. We observed a high-rate of seropositivity (86%) with 16 pts (14%) having a negative Spike IgG. Of the 86 minority patients included, 94% Blacks (30/32) and 87% (39/45) Hispanics showed seropositivity. The factors that contributed to significantly lower seroconversion rates included patients with Non-Hodgkin lymphoma (p=0.005), those who received cytotoxic chemotherapy (p=0.002), IVIG (p=0.01), CAR-T cell therapy (p=0.00002), and CD20 monoclonal antibodies (Ab) (p=0.0000008). Plasma cell neoplasms (p=0.02), immunomodulatory agents (p=0.01), and proteasome inhibitors (p=0.01) had significantly higher seroconversion rates, and those with a history of prior COVID-19 (11%, 12/106) had significantly higher antibody titers (p=0.0003). The positivity rate was 86% (37 seropositive, 6 seronegative) for autologous HSCT and 75% (3 seropositive, 1 seronegative) for allogeneic HSCT. No life-threatening AE were observed. We show high seroconversion rates after SARS-CoV-2 vaccination in non-White patients with hematologic malignancies treated with a wide spectrum of therapeutic modalities. Vaccination is safe, effective, and should be encouraged in most patients with hematologic malignancies. Our minorities based study could be employed as an educational tool to dispel myths and provide data driven evidence to overcome vaccine hesitancy.

Hispanics showed seropositivity. The factors that contributed to significantly lower seroconversion rates included patients with Non-Hodgkin lymphoma (p=0.005), those who received cytotoxic chemotherapy (p=0.002), IVIG (p=0.01), CAR-T cell therapy (p=0.00002), and CD20 monoclonal antibodies (Ab) (p=0.0000008). Plasma cell neoplasms (p=0.02), immunomodulatory agents (p=0.01), and proteasome inhibitors (p=0.01) had significantly higher seroconversion rates, and those with a history of prior COVID-19 (11%, 12/106) had significantly higher antibody titers (p=0.0003). The positivity rate was 86% (37 seropositive, 6 seronegative) for autologous HSCT and 75% (3 seropositive, 1 seronegative) for allogeneic HSCT. No life-threatening AE were observed. We show high seroconversion rates after SARS-CoV-2 vaccination in non-White patients with hematologic malignancies treated with a wide spectrum of therapeutic modalities. Vaccination is safe, effective, and should be encouraged in most patients with hematologic malignancies. Our minorities based study could be employed as an educational tool to dispel myths and provide data driven evidence to overcome vaccine hesitancy.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09. 13.21263365 doi: medRxiv preprint It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients with hematologic malignancies. 1, 2 The mRNA-based vaccines BNT162b2 (Pfizer) and mRNA-1273 (Moderna), and adenovirus-based Ad26.COV2.S (Johnson & Johnson) vaccine have robust safety and efficacy against COVID-19 among immunocompetent individuals, however, patients with cancer were not enrolled in these registration trials. [3] [4] [5] Emerging evidence suggests that despite the three COVID-19 vaccines with emergency use authorization (EUA) by the FDA inducing high levels of immunity in the general population, patients with hematologic malignancies have lower rates of seroconversion for the SARS-CoV-2 Spike IgG antibody (Spike IgG) and thus possibly lower protection against severe COVID-19. [6] [7] [8] In particular, smaller subgroups of patients with certain hematologic malignancies including chronic lymphocytic leukemia (CLL), multiple myeloma, and patients treated with B-cell depleting therapies (i.e. anti-CD20 monoclonal antibodies (MoAb), chimeric antigen receptor T-cell [CAR-T] therapy) and hematopoietic stem cell transplantation (HSCT), have shown markedly impaired antibody-mediated responses to COVID-19 vaccines. [9] [10] [11] [12] There currently exists, however, very little data on ethnicity specific responses in this particular patient population. We established a program of rapid vaccination and evaluation of antibodymediated response to all EUA COVID-19 vaccines in an inner city minority population to determine the factors that contribute to the poor seroconversion to COVID-19 vaccination in a broad range of patients with hematologic malignancies.

We conducted a cross-sectional cohort study of patients with hematologic malignancies in the outpatient practices of our institution between March 29, 2021 and July 8, 2021.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 . The . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263365 doi: medRxiv preprint seronegative) for autologous HSCT and 75% (3 seropositive, 1 seronegative) for allogeneic HSCT with no significant association with seroconversion, antibody titer, or time (greater or less than 1 year) since transplant. All patients who received anti-CD19 (Axi-cel) CAR-T therapy (0/6) were seronegative, and 1 patient that received BCMAdirected CAR-T therapy (Cilta-cel) was seropositive with no association between timing CAR-T cell infusion (greater or less than 1 year) and seroconversion or titer (median time to CAR-T therapy 17.5 months). The majority of patients, 64% and 53%, reported no adverse effects (AE) to the 1 st and 2 nd dose respectively. The most common AE were mild in severity and included sore arm, muscle aches, fatigue, and fever. No lifethreatening AE were observed.

Collectively, our data mirrors the current literature showing significantly lower rates of seroconversion in recipients following highly immunosuppressive therapies such as anti-CD20 therapies, and CAR-T therapy; however, we also noted that patients simply on cytotoxic chemotherapy are also at risk of poor seroconversion. Similar to the recent prospective cohort registry study through the Leukemia and Lymphoma Society, 14 we have noted that patients with myeloid malignancies and plasma cell neoplasms do quite well with COVID-19 vaccination despite their treatment history, with immunomodulatory agents and proteosome inhibitors actually correlating with higher seroconversion rates. We also observed an 86% seroconversion rate in autologous transplant recipients, higher than the previously reported 66%. 12 Recent anti-CD20 therapy (less than 6 months) and any time post CD19 CAR-T therapy predicts high rates of seronegativity showing that these therapies suppress normal B cell function for long . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263365 doi: medRxiv preprint durations after dosing. 15,16 It may be important to vaccinate all CAR-T therapy patients prior to lymphodepleting chemotherapy and consider treatment interruption for those patients on anti-CD20 therapy when feasible. In addition, despite our concordant findings with the current literature, race has not been a topic of discussion for successful seroconversion after vaccination. It is well known that race is an important contributor to morbidity and mortality in patients with COVID-19, 17 especially in the hematologic malignancy population, with non-White patients having a significantly higher risk of mortality than White patients, 1 and a higher rate of vaccine hesitancy. 18 Most studies described thus far do not stratify by race with those that do only ranging between 3.5-20% non-White patients.

To our knowledge, this is the first report on high seroconversion rates after SARS-CoV-2 vaccination in non-White patients with hematologic malignancies treated with a wide spectrum of therapeutic modalities. Vaccination is safe, effective, and should be encouraged in patients with hematologic malignancies. Our minorities based study could be employed as an educational tool to dispel myths and provide data driven evidence to overcome vaccine hesitancy.

We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263365 doi: medRxiv preprint

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Seroconversion rates following COVID-19 vaccination among patients with cancer

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy

Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity

Antibody response to SARS-CoV-2 vaccines

Acute leukemia (ALL, Acute lymphocytic leukemia

Adult T-cell Leukemia/Lymphoma; Burkitt's Lymphoma

Diffuse Large B-cell Lymphoma; Follicular Lymphoma

Mantle Cell Lymphoma; Marginal Zone Lymphoma; Mycosis Fungoides; Peripheral Tcell Lymphoma

Waldenstrom's Macroglobulinemia)

Plasma Cell Neoplasm (Multiple Myeloma; Amyloidosis; Plasma Cell Leukemia)

4 (3%) 4 (4%) 0 (0%) 1.00 Tyrosine kinase inhibitor, n (%) 5 (4%) 5 (5%) 0 (0%) 1.00 ADT, Androgen deprivation therapy; BCL-2, B cell lymphoma 2; BTK, Bruton's tyrosine kinase; OFS, Ovarian function suppression; AI, Aromatase inhibitors; IVIG, Intravenous immune globulin; TGFβ, Transforming growth factor beta.